US 7,576,204 B2
Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
Mitsuo Nagai, Tsukuba (Japan); Masashi Yoshida, Iwata (Japan); and Toshio Tsuchida, Iwata (Japan)
Assigned to Mercian Corporation, Tokyo (Japan); and Eisai R&D Management Co., Ltd., Tokyo (Japan)
Appl. No. 10/522,733
PCT Filed Jul. 31, 2003, PCT No. PCT/JP03/09752
§ 371(c)(1), (2), (4) Date Jan. 28, 2005,
PCT Pub. No. WO2004/011459, PCT Pub. Date Feb. 05, 2004.
Claims priority of application No. 2002-224111 (JP), filed on Jul. 31, 2002.
Prior Publication US 2006/0235002 A1, Oct. 19, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/497 (2006.01); C07D 411/00 (2006.01); C07D 313/04 (2006.01)
U.S. Cl. 544—374  [514/254.1; 549/271] 4 Claims
 
1. A compound represented by the formula (I):

OG Complex Work Unit Drawing
wherein R7 and R21 are the same or are different and represent
—O-benzoyl, or
RC(═Y)—O—, wherein Y represents an oxygen atom, and R represents
4-alkyl-piperazin-1-yl, alkyl, —O-phenyl, —N,N-dialkyl or —NH-phenyl, or
a pharmacologically acceptable salt thereof.